Inner and Outer Nuclear Layer Atrophy of the Retina as Novel and Distinguishing Biomarkers for Defining and Tracking Progressive Multiple Sclerosis
Abstract
Progressive multiple sclerosis (PMS) is a form of multiple sclerosis (MS) characterized by steady and gradual accumulation of disability. Optical coherence tomography (OCT) has emerged as a complementary tool to magnetic resonance imaging (MRI) with utility for tracking neurodegeneration in relapsing-remitting MS (RRMS). However, PMS is less well understood, hindering development of effective treatments. Herein, this project seeks to address these gaps by confirming and validating the predominance of INL (inner nuclear layer) and ONL (outer nuclear layer) retinal atrophy in PMS and evaluate their utility for the development of more specific PMS outcomes, and shedding light on the pathobiology of PMS. This project uses OCT and other data acquired from the SPRINT-MS trial, a 96-week, randomized, double-blind, placebo controlled study of the phosphodiesterase inhibitor ibudilast in 255 primary and secondary PMS patients. The projects first year milestones have been successfully completed, including all steps in the process of regulatory approval and data transfer. Work towards year two milestones of year two, specifically OCT segmentation, is underway. This is the first step towards obtaining high quality data to study whether rates of atrophy of ganglion cell + inner plexiform layer (GCIPL), INL and ONL are lower in ibudilast versus placebo treated PMS patients, and the relationships of OCT captured treatment effects with a broad spectrum of clinical and MRI measures.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2021
- Accession Number
- AD1158832
Entities
People
- Anna Duval
- Henrik Ehrhardt
- Shiv Saidha
Organizations
- Johns Hopkins University